Table 3 ELISA IgG geometric mean concentrations and proportions of subjects reaching above putative protective antibody concentration (i.e. ≥1.3 μg/mL) before and after vaccination in treatment groups and controls
RA without DMARD (n = 50) | RA with MTX (n = 10) | pSS without DMARD (n = 15) | Controls (n = 49) | |
|---|---|---|---|---|
Geometric mean concentrations (μg/mL): | ||||
6B prevaccination (95% CI) | 0.6 (0.3–1.0) | 1.3 (0.5–2.9) | 0.6 (0.2–2.0) | 0.8 (0.5–1.3) |
6B postvaccination (95% CI) | 3.4 (1.8–6.0) | 2.1 (0.8–5.6) | 2.3 (0.8–6.5) | 3.1 (1.9–5.0) |
P of increase | < 0.001 | 0.05 | 0.05 | < 0.001 |
23F prevaccination (95% CI) | 0.5 (0.3–0.8) | 1.0 (0.3–3.5) | 0.9 (0.4–1.9) | 0.6 (0.4–0.9) |
23F postvaccination (95% CI) | 2.5 (1.5–4.1) | 1.7 (0.7–3.9) | 3.5 (1.1–11.5) | 3.3 (2.0–5.5) |
P of increase | < 0.001 | 0.39 | 0.006 | < 0.001 |
Proportions of subjects with IgG concentration ≥ 1.3 μg/mL (%): | ||||
6B prevaccination (95% CI) | 38 (24–52) | 60 (23–97) | 33 (6–60) | 37 (23–51) |
6B postvaccination (95% CI) | 62 (48–76) | 70 (35–100) | 47 (18–75) | 65 (51–79) |
P of increase | 0.001 | 0.32 | 0.16 | < 0.001 |
23F prevaccination (95% CI) | 26 (13–39) | 40 (3–77) | 47 (18–75) | 29 (15–42) |
23F postvaccination (95% CI) | 68 (55–81) | 60 (23–97) | 73 (48–99) | 69 (56–83) |
P of increase | < 0.001 | 0.16 | 0.046 | < 0.001 |